Active Filter(s):
Details:
VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area: Genetic Disease Product Name: VX-121
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
The combination of VX-121/tezacaftor/VX-561 was first identified as having potential for increased efficacy based on its ability to drive higher levels of chloride transport compared to TRIKAFTA (elexacaftor/tezacaftor/ivacaftor /ivacaftor) in human bronchial epithelial cells.
Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area: Genetic Disease Product Name: VX-121
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Details:
VX-561 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis.
Lead Product(s): Deutivacaftor
Therapeutic Area: Genetic Disease Product Name: VX-561
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Vertex
Deal Size: $250.0 million Upfront Cash: $160.0 million
Deal Type: Agreement May 17, 2021